U.S. Markets open in 2 hrs 35 mins

Eventide Gilead Fund Ranked Best Performing Mutual Fund by The New York Times for the Five-Year Period Ending September 30, 2013 Based on Total Returns

BOSTON, MA--(Marketwired - Oct 21, 2013) -  The Eventide Gilead Fund ( NASDAQ : ETGLX ), a mutual fund practicing values-based investing, was ranked as the best performing mutual fund with over $50 Million in assets by The New York Times for the five-year period ending September 30, 2013 based on total returns. The New York Times ranking category was determined from the universe of NASDAQ-listed stock and bond funds with over $50 million in assets tracked by Morningstar, Inc. The Fund totaled $187.6M in AUM and generated a 5-year annualized return of 21.31% compared with the S&P 500 Index return of 7.57%, an annualized outperformance of 13.74%. According to The New York Times, the Fund also ranked as the third best performing fund with over $50 Million in assets for the one-year period ending September 30, 2013.

The following table highlights the Fund's performance over the past five years:

As of 9/30/2013   YTD return   1 year return   3 year annualized return   5 year annualized return   Since inception (07/08/2008) annualized return
Eventide Gilead Fund*   49.39%   55.71%   26.97%   21.31%   18.15%
S&P 500 Total Return Index   19.79%   19.34%   16.27%   7.57%   7.83%

The Eventide Gilead Fund is managed by Eventide Asset Management, LLC, a Boston-based investment advisory firm that is committed to investing in companies that excel at creating value for customers, employees, and society. The Fund was launched on July 8, 2008.

Expenses ratios: Gross Expenses 1.75%; Net Expenses 1.64%. The advisor has agreed to maintain the Fund's total annual operating expenses at 1.64% until at least October 31, 2014. Three-year, five-year and inception returns are annualized. The performance data quoted here represents past performance. Current performance may be lower or higher than the performance data quoted above. Past performance is no guarantee of future results. The investment return and principal value of an investment will fluctuate so that investor's shares, when redeemed, may be worth more or less than their original cost. Please review the fund's prospectus for more information regarding the fund's fees and expenses. Performance shown is for No-load Class shares (please see a prospectus for information about other share classes). For performance information current to the most recent month-end, please call toll-free 877-771-EVEN (3836).

New York Times Ratings and Classifications do not constitute and are not intended to constitute investment advice. As a result, you should not make an investment decision on the basis of this information. Rather, you should use this for informational purposes only.

Morningstar is an investment research firm that compiles and analyzes fund, stock, and general market data.

The NASDAQ is an electronic exchange, where investors can buy and sell stocks and mutual funds.

The S&P 500 is an index created by Standard & Poor's Corp and is considered to represent the performance of the stock market generally and is not a product available for purchase.

Mutual Funds involve risk including the possible loss of principal. The fund can invest in smaller-sized companies which may experience higher failure rates than larger companies and they normally have a lower trading volume than larger companies. The Fund's ethical values screening criteria could cause it to underperform similar funds that do not have such screening criteria. The fund can have risk associated with the biotechnology and pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the U.S. Food and Drug Administration. The fund can have risk related to option investing. There are special risks associated with investments in foreign companies including exposure to currency fluctuations, less efficient trading markets, political instability and differing auditing and legal standards. The fund can have risk associated with a higher portfolio turnover which could result in higher transactional costs.

An investor should consider the Fund's investment objectives, risks, charges and expenses carefully before investing or sending money. This and other important information about the Eventide Gilead Fund can be found in the Fund's prospectus. Please read the prospectus carefully before investing. To obtain a current prospectus please call the fund, toll free at 877-771- EVEN (3836). You can also obtain a prospectus at www.eventidefunds.com. The Eventide Gilead Fund is distributed by Northern Lights Distributors, LLC, which is not affiliated with Eventide Asset Management, LLC.